Condition: Appendiceal Cancer · Colorectal Adenocarcinoma · Peritoneal Metastases · Sponsor: Yale University
This study will evaluate the role of mass-based response testing (MRT) to select and deliver personalized hyperthermic intraperitoneal chemotherapy (HIPEC) regimens to patients with peritoneal metastasis (PM) from high-grade appendiceal adenocarcinomas (HGAA) and colorectal cancer (CRC).
This description comes directly from the study's public registry record.
Wumi Jemiseye, MPH · 203-737-4475 · wumi.jemiseye@yale.edu
Rodolfo N Molina, MD · 203-737-4475 · Rodolfo.molina@yale.edu
Always discuss trial participation with your own doctor first.
| Yale New Haven Hospital | New Haven, Connecticut, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07291180